Rapt Therapeutics Inc (OQ:RAPT)

Mar 11, 2024 09:00 pm ET
RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against RAPT Therapeutics, Inc. (“RAPT” or the “Company”) (NASDAQ: RAPT) on behalf of RAPT stockholders. Our investigation concerns...
Mar 07, 2024 04:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. (“RAPT” or the “Company”) (NASDAQ: RAPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.    The...
Mar 07, 2024 08:00 am ET
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases...
Mar 05, 2024 04:30 pm ET
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases...
Feb 28, 2024 03:05 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. (“RAPT” or the “Company”) (NASDAQ: RAPT).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.    The...
Feb 26, 2024 04:00 am ET
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RAPT Therapeutics, Inc. (“RAPT” or “the Company”) (NASDAQ: RAPT). Investors who purchased RAPT securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/RAPT.
Feb 21, 2024 01:52 pm ET
RAPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Investors of RAPT Therapeutics, Inc. (NASDAQ: RAPT)
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of RAPT Therapeutics, Inc. (NASDAQ: RAPT) (“RAPT”). On February 20, 2024, RAPT...
Feb 21, 2024 11:41 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. (“RAPT” or the “Company”) (NASDAQ: RAPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  The...
Feb 20, 2024 02:47 pm ET
Investigation of RAPT Therapeutics, Inc. (RAPT) Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC is investigating whether RAPT Therapeutics, Inc. (“RAPT Therapeutics,” or the “Company”) (NASDAQ: RAPT) complied with federal securities laws. On February 20, 2024, the Company “announced that the U.S. Food and Drug...
Feb 20, 2024 07:30 am ET
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
Feb 13, 2024 08:00 am ET
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases...
Jan 31, 2024 08:00 am ET
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases...
Jan 02, 2024 08:00 am ET
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases...
Nov 27, 2023 08:00 am ET
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
Nov 13, 2023 08:00 am ET
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases...
Nov 03, 2023 12:00 pm ET
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients wit
Median progression-free survival (PFS) of 6.3 months in PD-L1 positive patients at time of data cut off - Confirmed ORR of 50% in patients with PD-L1 high expression (TPS ≥50%) and 38% in patients with PD-L1 low expression (TPS 1-49%) - RAPT to...
Nov 01, 2023 04:05 pm ET
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases...
Oct 18, 2023 09:00 am ET
RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases...
Aug 30, 2023 04:05 pm ET
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases...
Aug 11, 2023 08:00 am ET
RAPT Therapeutics Reports Second Quarter 2023 Financial Results
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases...
Jun 07, 2023 08:00 am ET
RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases...
May 25, 2023 05:00 pm ET
RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases...
May 11, 2023 08:00 am ET
RAPT Therapeutics Reports First Quarter 2023 Financial Results
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases...
May 03, 2023 08:00 am ET
RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases...
Apr 26, 2023 04:19 pm ET
RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases...
Apr 03, 2023 01:10 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
NEW YORK, April 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Mar 29, 2023 08:00 am ET
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases...
Mar 26, 2023 06:02 pm ET
RAPT Therapeutics, Inc.: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm advises RAPT Therapeutics, Inc. (“RAPT Therapeutics,” or the “Company”) (NASDAQ: RAPT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors....
Mar 22, 2023 08:20 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
NEW YORK, March 22, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Mar 22, 2023 07:25 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
NEW YORK, March 22, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Mar 20, 2023 05:57 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
Pomerantz LLP is investigating claims on behalf of investors of  RAPT Therapeutics, Inc. (“RAPT” or the “Company”) (NASDAQ: RAPT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Mar 20, 2023 01:05 pm ET
Investigation of RAPT Therapeutics, Inc. (RAPT) Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC is investigating whether RAPT Therapeutics, Inc. (“RAPT Therapeutics,” or the “Company”) (NASDAQ: RAPT) complied with federal securities laws. On March 14, 2023, the Company disclosed that for its “Phase 2b trial of RPT193 in...
Mar 14, 2023 08:00 am ET
RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases...
Feb 07, 2023 08:00 am ET
RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
Jan 03, 2023 08:00 am ET
RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
Dec 08, 2022 06:30 am ET
RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
Nov 30, 2022 07:05 pm ET
RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress
RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet...
Nov 17, 2022 09:38 pm ET
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet...
Nov 17, 2022 04:24 pm ET
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet...
Nov 10, 2022 08:00 am ET
RAPT Therapeutics Reports Third Quarter 2022 Financial Results
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
Nov 09, 2022 08:00 am ET
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
Sep 28, 2022 08:00 am ET
RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
Aug 31, 2022 08:00 am ET
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
Aug 11, 2022 08:00 am ET
RAPT Therapeutics Reports Second Quarter 2022 Financial Results
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
May 25, 2022 08:00 am ET
RAPT Therapeutics Announces Private Placement Financing of $50 Million
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
May 23, 2022 08:00 am ET
RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
May 11, 2022 08:00 am ET
RAPT Therapeutics Reports First Quarter 2022 Financial Results
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
May 04, 2022 08:00 am ET
RAPT Therapeutics Expands Leadership Team with Multiple Key Hires
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
Mar 28, 2022 08:00 am ET
RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
Mar 10, 2022 08:00 am ET
RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
Feb 09, 2022 08:00 am ET
RAPT Therapeutics to Participate in the 11th Annual SVB Leerink Healthcare Conference
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
Jan 04, 2022 08:00 am ET
RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
Nov 10, 2021 04:05 pm ET
RAPT Therapeutics Reports Third Quarter 2021 Financial Results
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
Nov 09, 2021 04:01 pm ET
RAPT Therapeutics Appoints Industry Veteran Lori Lyons-Williams to its Board of Directors
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
Nov 08, 2021 08:00 am ET
RAPT Therapeutics to Participate in Upcoming Investor Conferences
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory...
Oct 18, 2021 08:00 am ET
RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease Summit
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Sep 30, 2021 09:15 am ET
RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Sep 20, 2021 08:00 am ET
RAPT Therapeutics to Present at the 2021 Cantor Virtual Healthcare Conference
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Sep 20, 2021 08:00 am ET
RAPT Therapeutics to Present RPT193 Phase 1b Data at 30th European Academy of Dermatology and Venereology Congress
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Sep 03, 2021 08:00 am ET
RAPT Therapeutics to Present at Upcoming Investor Conferences
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Aug 11, 2021 08:00 am ET
RAPT Therapeutics Reports Second Quarter 2021 Financial Results
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Jun 21, 2021 08:30 am ET
Thinking about buying stock in Anavex Life Sciences, Globalstar, Rapt Therapeutics, Aytu Biopharma, or Evofem Biosciences?
NEW YORK, June 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVXL, GSAT, RAPT, AYTU, and EVFM.
Jun 18, 2021 12:24 pm ET
RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Jun 15, 2021 11:07 pm ET
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Jun 15, 2021 08:30 am ET
Thinking about buying stock in Ocugen, Rapt Therapeutics, ContextLogic, OpGen, or Clean Energy Fuels?
NEW YORK, June 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCGN, RAPT, WISH, OPGN, and CLNE.
Jun 14, 2021 04:01 pm ET
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Jun 14, 2021 08:00 am ET
RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Jun 13, 2021 04:00 pm ET
RAPT Therapeutics to Report Top Line Data from Phase 1b Trial of RPT193 in Atopic Dermatitis
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
May 20, 2021 04:00 pm ET
RAPT Therapeutics to Present at the UBS Global Healthcare Virtual Conference
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
May 11, 2021 08:00 am ET
RAPT Therapeutics Reports First Quarter 2021 Financial Results
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Mar 22, 2021 08:00 am ET
RAPT Therapeutics Completes Enrollment in Phase 1b Trial of RPT193 in Atopic Dermatitis
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Mar 11, 2021 08:00 am ET
RAPT Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Mar 10, 2021 04:30 pm ET
RAPT Therapeutics to Report Promising Preclinical Studies Supporting its Pipeline of Immunotherapy Platforms at AACR
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Mar 03, 2021 08:00 am ET
RAPT Therapeutics to Participate in Two Investor Conferences in March
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Feb 19, 2021 08:00 am ET
RAPT Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Jan 05, 2021 08:00 am ET
RAPT Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Nov 23, 2020 08:00 am ET
RAPT Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Nov 16, 2020 08:00 am ET
RAPT Therapeutics Reports Third Quarter 2020 Financial Results
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Nov 16, 2020 07:30 am ET
RAPT Therapeutics Reports Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Nov 15, 2020 07:30 am ET
RAPT Therapeutics to Announce Initial Data from Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Nov 13, 2020 08:00 am ET
RAPT Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Oct 14, 2020 08:00 am ET
RAPT Therapeutics Appoints Lisa Butterfield, Ph.D., and Lawrence Fong, M.D., to Scientific Advisory Board
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Sep 03, 2020 08:00 am ET
RAPT Therapeutics to Present at Upcoming Virtual Investor Conferences
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Aug 13, 2020 10:47 am ET
RAPT Therapeutics Reports Second Quarter 2020 Financial Results
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Aug 05, 2020 08:00 am ET
RAPT Therapeutics Appoints Phyllis Loud Gray as Vice President of Human Resources
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Jun 18, 2020 04:05 pm ET
Peter Svennilson Elected to RAPT Therapeutics Board of Directors
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Jun 17, 2020 08:00 am ET
RAPT Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
May 29, 2020 08:00 am ET
RAPT Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Virtual Scientific Program
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
May 26, 2020 08:00 am ET
RAPT Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
May 15, 2020 08:00 am ET
RAPT Therapeutics Highlights Early Results for RPT193 at Society for Investigative Dermatology Meeting
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
May 14, 2020 08:00 am ET
RAPT Therapeutics Reports First Quarter 2020 Financial Results
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
May 12, 2020 08:00 am ET
RAPT Therapeutics to Present at the UBS Virtual Global Healthcare Conference
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Mar 30, 2020 08:00 am ET
RAPT Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Business Update
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Mar 04, 2020 08:00 am ET
RAPT Therapeutics Announces Management Promotions
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Feb 19, 2020 08:00 am ET
RAPT Therapeutics Announces Upcoming Investor Conference Presentations
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Feb 07, 2020 06:45 am ET
RAPT Therapeutics Announces Pricing of $75 Million Public Offering
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Feb 04, 2020 05:43 pm ET
RAPT Therapeutics Announces Proposed Offering of Common Stock
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Jan 07, 2020 08:00 am ET
RAPT Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Dec 16, 2019 08:00 am ET
RAPT Therapeutics to be Added to the Russell 2000® and Russell Microcap® Indices
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Dec 11, 2019 08:00 am ET
RAPT Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Dec 10, 2019 08:00 am ET
RAPT Therapeutics Appoints Mary Ann Gray, Ph.D., to Board of Directors
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Dec 04, 2019 08:00 am ET
RAPT Therapeutics Appoints Rodney Young as Chief Financial Officer
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Dec 03, 2019 04:05 pm ET
RAPT Therapeutics and Hanmi Pharmaceutical Announce Collaboration to Develop and Commercialize FLX475 in Asia
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and...
Oct 30, 2019 08:49 pm ET
RAPT Therapeutics Announces Pricing of Initial Public Offering
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the pricing of its initial public offering of 3,000,000 shares of common stock at a public offering price of $12.00 per share.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.